BIOCRYST PHARMACEUTICALS INC Annual Operating Lease, Payments in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Biocryst Pharmaceuticals Inc quarterly/annual Operating Lease, Payments history and growth rate from 2019 to 2023.
  • Biocryst Pharmaceuticals Inc Operating Lease, Payments for the quarter ending March 31, 2024 was $525K, a 24.1% increase year-over-year.
  • Biocryst Pharmaceuticals Inc Operating Lease, Payments for the twelve months ending March 31, 2024 was $2.02M, a 44% increase year-over-year.
  • Biocryst Pharmaceuticals Inc annual Operating Lease, Payments for 2023 was $1.92M, a 23.5% increase from 2022.
  • Biocryst Pharmaceuticals Inc annual Operating Lease, Payments for 2022 was $1.56M, a 4.36% increase from 2021.
  • Biocryst Pharmaceuticals Inc annual Operating Lease, Payments for 2021 was $1.49M, a 12.1% decline from 2020.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $1.92M +$365K +23.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $1.56M +$65K +4.36% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $1.49M -$206K -12.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $1.7M +$239K +16.4% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-28
2019 $1.46M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.